SCHEMBL5656453

SCHEMBL5656453

Cn1cnnc1C(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)nc1nnnn12

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FNTA P49354 12/20 0.59
FNTB P49356 12/20 0.59
PGGT1B P53609 2/20 0.57
CHEK1 O14757 1/20 0.35
LIMK1 P53667 1/20 0.35
MAPK14 Q16539 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
CNR1 P21554 1/20 0.31
IDO1 P14902 1/20 0.31
KDM5B Q9UGL1 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5659774 0.94 FNTA (0.52) FNTAFNTBPGGT1BCHEK1LIMK1
SCHEMBL5656227 0.92 FNTA (0.50) FNTAFNTBPGGT1B
SCHEMBL14588487 0.86 FNTA (0.51) FNTAFNTBPGGT1BCHEK1LIMK1
SCHEMBL5659913 0.83 FNTA (0.70) FNTAFNTBPGGT1BMEN1KMT2A
SCHEMBL5655411 0.80 FNTA (0.46) FNTAFNTBPGGT1BCHEK1LIMK1
SCHEMBL14588483 0.79 FNTA (0.52) FNTAFNTBPGGT1BCHEK1LIMK1
SCHEMBL5016825 0.79 FNTA (0.61) FNTAFNTBPGGT1BIDO1
SCHEMBL5655368 0.78 FNTA (0.78) FNTAFNTBPGGT1BCHEK1LIMK1
SCHEMBL5543925 0.78 FNTA (0.60) FNTAFNTBPGGT1BIDO1
SCHEMBL14588485 0.78 FNTA (0.51) FNTAFNTBPGGT1BCHEK1LIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7173040-B2 Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-06 US disclosed
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties JANSSEN-CILAG S.A. (FR) 2004-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048882-A1 Farnesyl transferase inhibiting 6-(substituted phenyl) Methy)-quinoline and quinazoline derinazoline derivaties FNTB, FNTA, CYP7A1 FNTA 2/4885FNTB 1/4885PGGT1B 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.